Skip to main content

Table 4 Impact of study characteristics to the effects of atorvastatin therapy on serum adiponectin concentrations: results of subgroup analyses

From: Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials

Study characteristicsWMD of serum adiponectin concentration (ug/ml)
Comparisons (patients), nI2WMD [95% CI]p1p2
R, DB, PC studies
 Yes4 (396)73%− 1.02 [−2.27, 0.22]0.11 
 No10 (535)50%0.06 [−0.64, 0.77]0.860.14
Crossover studies
 Yes2 (196)0%−0.13 [− 0.72, 0.46]0.66 
 No12 (735)65%−0.33 [−1.13, 0.47]0.420.70
Patients with DM
 Yes5 (396)59%−0.95 [−2.18, 0.29]0.13 
 No9 (535)57%0.03 [−0.65, 0.71]0.960.18
Patients with dyslipidemia
 Yes7 (398)0%−0.28 [−0.75, 0.19]0.24 
 No7 (533)79%−0.42 [−1.71, 0.87]0.520.84
Mean age
 ≤ 56 years7 (419)80%0.02 [−1.13, 1.18]0.97 
 > 56 years7 (512)0%−0.54 [−1.13, 0.04]0.070.39
Male
 ≤ 52%8 (499)56%0.09 [−0.63, 0.81]0.81 
 > 52%6 (432)65%−0.88 [−2.02, 0.27]0.130.16
BMI
 ≤ 26 kg/m29 (535)57%0.03 [−0.65, 0.71]0.94 
 > 26 kg/m25 (396)59%−0.95 [−2.18, 0.29]0.130.18
Dose
 10 mg6 (407)12%−0.32 [− 0.92, 0.28]0.29 
 20 mg3 (206)84%−1.15 [−3.11, 0.81]0.25 
 40 mg3 (159)75%0.67 [−1.18, 2.51]0.84 
 80 mg2 (159)0%−0.35 [−1.42, 0.71]0.520.62
Follow-up duration
 ≤ 8 weeks8 (520)0%−0.19 [− 0.62, 0.24]0.40 
 > 8 weeks6 (411)82%−0.59 [−2.20, 1.02]0.470.64
Adiponectin assay
 ELISA11 (720)38%−0.01 [− 0.57, 0.54]0.96 
 RIA3 (211)85%−1.48 [−3.74, 0.79]0.200.22
  1. Abbreviations: WMD weighed mean difference, CI confidence interval, R random, DB double-blinded, PC placebo-controlled, BMI body mass index, ELISA enzyme-linked immunosorbent assay, RIA radioimmunoassay
  2. 1p values for subgroup effects
  3. 2p values for subgroup interaction